Tissue Regenix Group PLC Launch of BioSurgery and new distributor agreement (8572F)
February 26 2018 - 2:01AM
UK Regulatory
TIDMTRX
RNS Number : 8572F
Tissue Regenix Group PLC
26 February 2018
Tissue Regenix Group plc
Launch of TRX BioSurgery and new distributor agreement
Leeds, 26 February 2018 - Tissue Regenix Group (AIM:TRX)
("Tissue Regenix" or the "Group"), the regenerative medical devices
company, today announces the launch of operating division, "TRX
BioSurgery".
DermaPure(R), a decellularized, room-temperature stable dermal
allograft will be the flagship product under the TRX BioSurgery
division. Currently commercialised under Tissue Regenix Wound Care,
Inc., which will begin operating as 'TRX BioSurgery', DermaPure has
proven successful in multiple surgical applications. Due to
DermaPure's impressive single application clinical outcomes, it has
been adopted by surgeons within the acute surgical, wound
reconstruction, and traditional advanced wound care markets. In
particular, DermaPure has seen significant uptake in the
orthopaedic trauma and urogynaecology segments, where treatment
innovation has been in high demand.
In order to further expand this opportunity, Tissue Regenix has
entered an exclusive distribution partnership with ARMS Medical, a
specialist distributor in the urogynaecology segment. The
multi-year agreement gives ARMS Medical exclusive rights to
distribute DermaPure to hospitals and surgeons throughout the
United States for use in urology and gynecology procedures. The
partnership will allow Tissue Regenix's direct sales force to
maintain their focus on soft tissue regeneration in the Wound,
Plastics, Orthopaedics and General Surgery markets.
Steve Couldwell, CEO, Tissue Regenix Group commented: "We are
excited to announce the launch of the BioSurgery division.
Progressing from traditional wound care clinical settings to
surgical applications is a natural evolution for DermaPure, which
has proven to be clinically efficient in just a single application.
Our partnership with ARMS Medical, who are known for bringing
innovation to women's pelvic health solutions, allows us to
leverage their strong relationships with Key Opinion Leaders in the
urogynaecology space to further access this market, whilst also
maintaining commercial focus in our other key areas."
TRX BioSurgery will be exhibiting at the Society of Urodynamics,
Female Pelvic Medicine, & Urogenital Reconstruction (SUFU),
February 27 - March 3, 2018, Austin, TX.
For more Information:
Tissue Regenix Group plc Tel: 0330
Steve Couldwell CEO 430 3073
Caitlin Pearson Head of Communications / 07920272
441
---------------------------------------- ------------
Jefferies International Ltd Tel: 020
Simon Hardy / Christopher Binks 7029 8000
---------------------------------------- ------------
FTI Consulting Tel: 0203
Brett Pollard / Mo Noonan/ Rob Winder 727 1000
======================================== ============
About Tissue Regenix
Tissue Regenix is a leading medical devices company in the field
of regenerative medicine. Tissue Regenix was formed in 2006 when it
was spun-out from the University of Leeds, UK. The company's
patented decellularisation ('dCELL(R) ') technology removes DNA and
other cellular material from animal and human soft tissue leaving
an acellular tissue scaffold which is not rejected by the patient's
body and can then be used to repair diseased or worn out body
parts. Current applications address many critical clinical needs
such as sports medicine, heart valve replacement and wound
care.
In November 2012 Tissue Regenix Group plc set up a subsidiary
company in the United States - 'Tissue Regenix Wound Care Inc.',
January 2016 saw the establishment of joint venture GBM-V, a multi-
tissue bank based in Rostock, Germany.
In August 2017 Tissue Regenix acquired CellRight Technologies(R)
, a biotech company that specializes in regenerative medicine and
is dedicated to the development of innovative osteoinductive and
wound care scaffolds that enhance healing opportunities of defects
created by trauma and disease. CellRight's human osteobiologics may
be used in spine, trauma, general orthopedic, foot & ankle,
dental, and sports medicine surgical procedures.
This information is provided by RNS
The company news service from the London Stock Exchange
END
CNTTAMJTMBMTTJP
(END) Dow Jones Newswires
February 26, 2018 02:01 ET (07:01 GMT)
Tissue Regenix (LSE:TRX)
Historical Stock Chart
From Apr 2024 to May 2024
Tissue Regenix (LSE:TRX)
Historical Stock Chart
From May 2023 to May 2024